Company profile
Aclaris Therapeutics, Inc.
NASDAQ: ACRS · Healthcare · Biotechnology
#660 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
47DFH 42DQ 64GM 21SS 62
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$8.4M
Rev growth YoY (TTM)
-52.9%
Net income (FY)
-$64.9M
Employees
71
as of 2026-08-11
Market cap
$824.0M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.8M$7.8M2025
Net income-$64.9M-$64.9M2025
Operating income-$76.4M-$76.4M2025
Total assets$160.5M$160.5M2025
Liabilities$57.4M$57.4M2025
Equity$103.1M$103.1M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License and Service76%
Contract research24%
By geography
Not disclosed.
The read
What is Aclaris Therapeutics, Inc.’s revenue?
Aclaris Therapeutics, Inc. booked $7.8M in FY2025 revenue, contracting 58% year over year — slower than 84% of Healthcare companies we track, at a -829.6% net margin.
Peers · Healthcare
Nextleaf Solutions Ltd.57CCoya Therapeutics, Inc.48DCogent Biosciences, Inc.48DPulmatrix, Inc.46DCrinetics Pharmaceuticals, Inc.53DBolt Biotherapeutics, Inc.39DNeighbors
Delaware →Key facts
CEONeal S. Walker
SectorHealthcare
IndustryBiotechnology
HeadquartersWayne, PA
ExchangeNASDAQ: ACRS
Employees71
IPO date2015-10-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.